Medtronic PLC $MDT Shares Purchased by CORDA Investment Management LLC.

CORDA Investment Management LLC. grew its position in shares of Medtronic PLC (NYSE:MDT) by 9.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 296,967 shares of the medical technology company’s stock after acquiring an additional 24,604 shares during the quarter. Medtronic comprises 1.4% of CORDA Investment Management LLC.’s portfolio, making the stock its 28th biggest position. CORDA Investment Management LLC.’s holdings in Medtronic were worth $23,232,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. New England Capital Financial Advisors LLC increased its position in Medtronic by 7.8% during the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after purchasing an additional 101 shares in the last quarter. Ipsen Advisor Group LLC grew its stake in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after buying an additional 101 shares during the period. Quadrant Capital Group LLC increased its position in shares of Medtronic by 0.3% in the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock worth $3,120,000 after acquiring an additional 101 shares in the last quarter. Rossby Financial LCC raised its stake in shares of Medtronic by 5.1% in the 4th quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after acquiring an additional 107 shares during the period. Finally, Wealthspire Retirement LLC raised its stake in shares of Medtronic by 5.0% in the 4th quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock valued at $232,000 after acquiring an additional 114 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Price Performance

MDT stock opened at $94.13 on Thursday. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The stock’s 50 day moving average is $83.88 and its two-hundred day moving average is $86.08. The company has a market capitalization of $120.49 billion, a PE ratio of 25.24, a P/E/G ratio of 2.47 and a beta of 0.55.

Medtronic (NYSE:MDT) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same period in the prior year, the business posted $1.62 EPS. The business’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts predict that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is presently 77.21%.

Analyst Ratings Changes

A number of analysts recently weighed in on MDT shares. Mizuho decreased their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Wednesday, June 3rd. Evercore set a $105.00 target price on Medtronic in a research note on Monday, July 6th. Wells Fargo & Company reduced their price target on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, June 4th. UBS Group upgraded Medtronic from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $100.00 in a report on Tuesday, July 28th. Finally, The Goldman Sachs Group dropped their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.83.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).